BiotechTube
Home/Amarin Corporation/Michael W. Kalb
MW

Michael W. Kalb

Board Director

Amarin Corporation

Therapeutic Areas

CardiovascularMetabolic Disorders

Amarin Corporation Pipeline

DrugIndicationPhase
VASCEPA® / VAZKEPA® (Icosapent Ethyl)Cardiovascular Risk ReductionApproved
VASCEPA® (Icosapent Ethyl)Severe Hypertriglyceridemia (≥500 mg/dL)Approved

Leadership Team at Amarin Corporation

PH
Patrick Holt
President, Chief Executive Officer, Director
AB
Aaron Berg
Executive Vice President, Chief Financial Officer
KM
Karim Mikhail
Executive Vice President, Chief Commercial Officer
SB
Steven B. Ketchum
Executive Vice President, President of Research & Development, Chief Scientific Officer
MG
Mark G. Hibbard
Senior Vice President, General Counsel
PW
Per Wold-Olsen
Chairman of the Board of Directors
GM
Graham McVeigh
Board Director
DS
David Stack
Board Director
BB
Brittany Bradrick
Board Director
View full Amarin Corporation profile